<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02860858</url>
  </required_header>
  <id_info>
    <org_study_id>18265_CREC032/59BPs</org_study_id>
    <nct_id>NCT02860858</nct_id>
  </id_info>
  <brief_title>Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)</brief_title>
  <official_title>Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajavithi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rajavithi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To evaluate the efficacy of intravitreal aflibercept injection on visual acuity in&#xD;
      patients with symptomatic macular PCV.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 30, 2016</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">August 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity (BCVA)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Symtomatic Macular Polypoidal Choroidal Vasculopathy</condition>
  <arm_group>
    <arm_group_label>Aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intravitreous aflibercept injection</intervention_name>
    <arm_group_label>Aflibercept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female &gt;/= 18 years&#xD;
&#xD;
          -  Confirmed diagnosis of symptomatic macular PCV in the study eye defined by: - Active&#xD;
             macular polypoidal lesions shown by ICGA and - Presence of serosanguinous maculopathy&#xD;
&#xD;
          -  BCVA letter score between 78-24 using ETDRS visual acuity chart measured at 4 meters&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with systemic anti-VEGF drugs within 6 months prior to Baseline&#xD;
             (e.g., sorafenib [Nexavar®], sunitinib [Sutent®], bevacizumab [Avastin®])&#xD;
&#xD;
        Study eye:&#xD;
&#xD;
          -  Active ocular inflammation or infection (ocular or periocular)&#xD;
&#xD;
          -  Uncontrolled intraocular hypertension or glaucoma (IOP&gt; 30 mmPIg) despite treatment&#xD;
             with anti-glaucoma medication&#xD;
&#xD;
          -  Predominantly-scarred PCV lesions&#xD;
&#xD;
          -  Ocular disorders in the study eye (e.g. cataract, retinal vascular occlusion, diabetic&#xD;
             retinopathy) that, in the opinion of the investigator may confound interpretation of&#xD;
             study results or compromise VA or require medical or surgical intervention during the&#xD;
             study period&#xD;
&#xD;
          -  Prior treatment with verteporfin PDT, external-beam radiation, subfoveal or&#xD;
             extrafoveal focal laser photocoagulation, submacular surgery, or transpupillary&#xD;
             thermotherapy&#xD;
&#xD;
          -  Prior treatment with any anti-VEGF compound or any investigational treatment&#xD;
&#xD;
          -  Treatment with intravitreal or subtenon corticosteroid injection or device&#xD;
             implantation within 90 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rajavithi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>July 4, 2016</study_first_submitted>
  <study_first_submitted_qc>August 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2016</study_first_posted>
  <last_update_submitted>October 21, 2020</last_update_submitted>
  <last_update_submitted_qc>October 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

